title: 1 Acyl-2 acetyl-sn-glycero-3 phosphocholine decreases the susceptibility of low-density lipoprotein to oxidative modification by copper ions, monocytes or endothelial cells.
abstract: The effects of platelet-activating factor (PAF) and its analogue, 1 acyl-2 acetyl-sn-glycero-3 phosphocholine (1 acyl-2 acetyl-GPC), were investigated on the oxidative modification of low-density lipoprotein (LDL) by copper ions, U937 monocyte-like cells or endothelial cells, by determination of the lipid peroxidation end products (TBARS) content and measurement of the electrophoretic mobility of the particle. 1 Acyl-2 acetyl-GPC, in the concentration range 1-5 micrograms/ml, inhibited LDL oxidation in a dose-dependent manner in the three systems, whereas PAF had no effect. The protective effect of 1 acyl-2 acetyl-GPC was markedly more important when oxidative modification was performed with endothelial cells, leading to total inhibition at 5 micrograms/ml. At the same concentration, the TBARS production was inhibited by 60% and 20% with monocytes and copper ions, respectively. The degradation by J774 macrophage-like cells of LDL modified by copper ions, U937 monocyte-like cells or endothelial cells was also inhibited when modification was performed in the presence of 1 acyl-2 acetyl-GPC. Furthermore, preincubation of the LDL particle with 1 acyl-2 acetyl-GPC before modification protected the lipoprotein against oxidation, whereas preincubation of the cultured cells with the phospholipid had no effect. Thus 1 acyl-2 acetyl-GPC decreases the susceptibility of the LDL particle to oxidative modification, possibly by intercalation within the lipid phase of the particle. Since LDL oxidation is believed to play an important role in the initiation and progression of atherosclerosis, this inhibitory effect of 1 acyl-2 acetyl-GPC might be of importance in view of the fact that this phospholipid is produced concomitantly with PAF in some inflammatory cells.
authors.affiliation: Laboratoire de Biochimie, Faculté de Médecine Saint-Antoine, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Maziere
authors.forename: M
authors.initials: M
authors.lastname: Djavahery-Mergny
authors.forename: M
authors.initials: M
authors.lastname: Auclair
authors.forename: J C
authors.initials: JC
authors.lastname: Maziere
mesh_terms: D002460:Cell Line; D003300:Copper / Q000494:pharmacology*; D004727:Endothelium / Q000378:metabolism; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism*; D009000:Monocytes / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects; D010972:Platelet Activating Factor / Q000031:analogs & derivatives* / Q000494:pharmacology; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
chemical_list: C069030:1-acyl-2-acetyl-sn-glycero-3-phosphocholine; D008077:Lipoproteins, LDL; D010972:Platelet Activating Factor; D017392:Thiobarbituric Acid Reactive Substances; D003300:Copper